Innovative Biopharmaceuticals from Oral Science
At Oragenics, we are focused on becoming the world leader in novel antibiotics targeted against some of the most prevalent and urgently needed infectious diseases.
Learn More About OragenicsExclusive Collaboration with Intrexon
Our exclusive channel collaboration arrangement with Intrexon contemplates the use of Intrexon’s advanced transgene and cell engineering platforms for the development and production of revolutionary lantibiotics and live biotherapeutic products (LBP).
Learn More About Our CollaborationsFighting Global Bacterial Antibiotic Resistance
Oragenics, in collaboration with Intrexon, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.
Learn More About LantibioticsAdjunctive Therapy for Oral Mucositis
Oragenics, in collaboration with Intrexon, is also in the process of developing live biotherapeutic products (LBP) to treat oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus.
Learn More About LBP
